US Patent Issued to Achillion Pharmaceuticals on March 4 for "Targeted dosing for the treatment of complement mediated disorders" (Connecticut, Washington Inventors)

ALEXANDRIA, Va., March 5 -- United States Patent no. 12,239,645, issued on March 4, was assigned to Achillion Pharmaceuticals Inc. (Boston).

"Targeted dosing for the treatment of complement mediated disorders" was invented by Mingjun Huang (Vancouver, Wash.) and Steven D. Podos (New Haven, Conn.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The dosages and methods described herein provide desirable pharmacokinetic (PK) and pharmacodynamics (PD) characteristics which inhibit alternative pathway complement activity, for example at least 85% or more inhibition of AP activity in vivo at dosages from about 120 mg to 200 mg BID that provides a plasma level Ctrough at least about 65 ng/ml, which provides sufficien...